David P. Meeker - 01 Feb 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
President and CEO, Director
Signature
/s/ Hunter Smith, Attorney-in-Fact for David Meeker
Issuer symbol
RYTM
Transactions as of
01 Feb 2024
Net transactions value
-$196,507
Form type
4
Filing time
05 Feb 2024, 18:53:36 UTC
Previous filing
30 Jun 2023
Next filing
21 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +14,125 +13% 125,460 01 Feb 2024 Direct F1
transaction RYTM Common Stock Sale $196,507 -4,361 -3.5% $45.06 121,099 01 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -14,125 -25% $0.000000 42,375 01 Feb 2024 Common Stock 14,125 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.